Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Stopped Samus is focusing all of their efforts in myelofibrosis on the new oral formulation of PU-H71.

Conditions

• Myelofibrosis
• Primary Myelofibrosis
• Post-polycythemia Vera Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis

Interventions

• DRUG: PU-H71
• DRUG: Ruxolitinib

Sponsor

Samus Therapeutics, Inc.